For example, García MJ et al. reported a prospective study including 207 Vedolizumab-treated patients and 628 Ustekinumab-treated patients who had TNF antagonist failure or intolerance from ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease): Vedolizumab was associated with a higher risk of treatment discontinuation compared with Ustekinumab, adjusted by corticosteroids at baseline, moderate-severe activity in Harvey-Bradshaw Index (HBI), and high levels of C-reactive protein at baseline (Garcia et al., 2024). The gene discussed is CRP; the disease is inflammatory bowel disease.